Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12

8 février 2018

10:12
Solevo Wellness, the first medical marijuana dispensary to open in the Greater Pittsburgh region and in Allegheny County, held an open house Wednesday, February 7th. Guests were invited to tour the 7,000 square foot facility and learn how medical...

10:00
Adventist Health System's whole-person care program choose Agfa DR to maximize existing investments, improve efficiency with cassette-less workflow, and gain access to intelligent MUSICA Image Processing software throughout their enterprise....

08:30
Janssen Research & Development, LLC (Janssen) and Johnson & Johnson will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer. The...

08:30
BiondVax Pharmaceuticals Ltd. , developer of a Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, and the European UNISEC consortium announced today they will co-host the Annual UNISEC Consortium Meeting, which...

08:11
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for ZYTIGA® (abiraterone acetate) in combination with prednisone for the treatment of patients...

08:03
In a continued effort to combat the opioid epidemic, Navitus Health Solutions, a pharmacy benefits solutions company, announced today that it is seeing positive results from its multi-faceted programs designed to promote safe opioid use. ...

08:00
Epic Sciences, Inc. (Epic) announces that it will present data, in conjunction with Endocyte, Inc., comparing its proprietary single cell CTC analysis to PSMA targeted imaging in mCRPC patients to provide insight into disease heterogeneity and...

08:00
DarioHealth Corp. , a leading global digital health company with mobile health and big data solutions, today announced it has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing...

07:40
Syndesi Therapeutics to leverage UCB's expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders with a first-in-class mechanism Series A financing of ?17 M from a syndicate of Belgium and international investors...

07:12
Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals, today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City. Steve Parkinson, President and CEO of...

07:00
PLENVU® is the first 1-litre PEG bowel preparation   PLENVU® is superior to MOVIPREP® in providing high-quality cleansing in the colon ascendens - an important area for adenoma detection  Norgine B.V. today announced that the marketing...

05:34
DT MedTech, LLC (DTM) a annoncé aujourd'hui que le prof. Beat Hintermann, chirurgien du pied et de la cheville de renommée mondiale et développeur de la nouvelle prothèse totale de la cheville semi-contrainte à deux composants, le système de...

03:30
Appoints Internationally Renowned Scientific Advisors  Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received...

01:22
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The updated label...


7 février 2018

23:15
ClinOne, a mobile clinical trial management solution, now allows sponsors to distribute study updates directly to their study patients through their secure messaging technology. Lack of study communication and updates have been linked to poor...

18:20
DT MedTech, LLC (DTM) announced today that Prof. Beat Hintermann, world-renowned foot and ankle surgeon and developer of the new, two-component, semi-constrained total ankle prosthesis, Hintermann Series H2tm Total Ankle Replacement System, has...

17:37
A new study reveals a mechanism by which the immune system may decide whether a bacterial species is a partner in bodily processes or an invader worthy of attack.  The study, led by NYU School of Medicine researchers...

17:21
Despite the 25-year focus on the build-up in brain tissues of one protein, amyloid beta, as the purported origin of Alzheimer's disease (AD), a new study argues that it is likely triggered instead by the failure of a system that clears wastes from...

17:01
A new study of genetic factors involved causing autism spectrum disorders (ASD) draws fresh attention to the impact these illnesses have on motor skills, and more broadly on cognitive function. "Diminished motor skills...

13:00
A first-of-its-kind double-blinded, crossover study of children with autism who were treated with their own cord blood showed the treatment to be safe and suggests improvement in socialization. The study, which was published this week in the medical...

12:15
BioMarin Pharmaceutical Inc. announced today that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase (NAGLU) with a...

11:58
Physicians at Lucile Packard Children's Hospital Stanford have performed open-heart surgery without a blood transfusion for the smallest infant ever to undergo such a procedure in North America. The surgery, on October...

10:45
Eurocine Vaccines initiates a phase I/II clinical study in older adults with its quadrivalent nasal influenza vaccine candidate Immunosetm FLU. The purpose of the study is to evaluate safety, tolerability, as well as serological and mucosal immune...

10:15
Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology drug development, announced today it has enrolled the first cohort of patients into its Phase I / II study of PT-112 as a single agent in relapsed or refractory...

10:08
Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced topline results from the MODIFY2 Phase 2 clinical trial of SB-061 for symptom management in mild-to-moderate osteoarthritis of the knee. The...

09:45
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced positive results from a recently completed Phase 1 proof-of-concept trial of...

09:32
Physicians and clinical researchers from the Medical College of Wisconsin (MCW), Froedtert Hospital, Children's Hospital of Wisconsin, and BloodCenter of Wisconsin have successfully used a new immunology treatment, chimeric antigen receptor (CAR)...

09:08
Galmed Pharmaceuticals, Ltd. , ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH and other liver diseases, today...

08:30
Therapix Biosciences Ltd. ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it has held a pre-Investigational New Drug (pre-IND)...

07:33
Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today that Alan Ezekowitz, CEO and President, will present an overview of the company...

07:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of Theravance Biopharma, Inc. to develop TD-1473, a first-in-class oral, gastrointestinal (GI) restricted pan-Janus...

06:59
Swedish Orphan Biovitrum AB (publ) (Sobitm) will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018. These data mark the company´s...

05:00
Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners, are celebrating  "National Cancer Prevention Day" (#NationalCancerPreventionDay ? February 7, 2018) by confirming a new, global milestone:...

02:00
Pharmapack Europe Expo - SCHOTT AG et ARaymond Life annoncent que les flacons SCHOTT adaptiQ® et les fermetures par simple pression en plastique ARaymondlife RayDyLyo®  sont confirmés en tant qu'ensemble de produits à utiliser avec les cellules de...


6 février 2018

19:30
Audentes Therapeutics, Inc. , a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an optimized clinical development...

19:30
Sangamo Therapeutics, Inc. today announced the presentation of initial safety data from the CHAMPIONS Study, the Phase 1/2 clinical trial evaluating SB-913 for the treatment of mucopolysaccharidosis (MPS) type II, a rare disease also known as Hunter...

13:49
Over the past several months, there have been many questions raised about the botanical substance known as kratom. Our concerns related to this product, and the actions we've taken, are rooted in sound science and are in the interest of protecting...

12:03
The Pulmonary Fibrosis Foundation (PFF) has launched a new Clinical Trial Finder, the first one of its kind for patients living with the deadly lung disease.  Patients can now quickly and easily navigate more than 100 clinical research opportunities...

12:00
Takeda Pharmaceuticals, U.S.A., Inc. ("Takeda") today announced the publication of a study utilizing a novel simulation model to predict treatment response in patients with moderately to severely active ulcerative colitis (UC) and help better...

11:08
Zymo Research Corp. has teamed up with the Blue Carbon Lab, an academic research group at Australia's Deakin University, and colleagues at the Portuguese Centre for Marine Sciences, University of Algarve, on the 'TeaComposition H2O' project. This is...

10:10
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Vaccibody AS is expanding their human clinical trial (phase IIa) for the study of a vaccine to treat HPV disease using the PharmaJet Stratis® needle-free...

09:45
Marken a étendu sa portée géographique et sa gamme de produits en 2017, renforçant sa position de leader dans le domaine des services de logistique et de chaîne d'approvisionnement pour les essais cliniques. L'augmentation de la demande en services...

09:15
A real-world study in more than 18,000 patients has demonstrated superior asthma control with the AeroChamber Plus* Flow-Vu* Anti-Static Valved Holding Chamber (VHC) compared with other chambers.[1] According to this new retrospective study,...

09:00
SANDY, Utah., Feb. 6, 2018 /PRNewswire-PRWeb/ --Utah Cord Bank (UCB) is pleased to announce that it has engaged in a consulting agreement with A3Cell and Dr. Barbara Krutchkoff* to help strategize its regulatory roadmap over the coming years. UCB...

09:00
Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today that the first patients were dosed in the company's Phase III study of P2B001, titled "A phase 3, twelve-week,...

08:00
TransCelerate BioPharma Inc., a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating research and development of innovative new therapies, has unveiled a new global campaign designed to...

08:00
Trovagene, Inc. , a precision medicine biotechnology company, today announced that the first patient has completed the first cycle of dosing with PCM-075 in combination with low-dose cytarabine in its Phase 1b/2 multicenter trial of patients with...

08:00
CellMax Life, a leading cancer diagnostics company enabling early cancer detection and management with globally affordable non-invasive blood tests, today announced results from a new 200-patient study showing that its circulating tumor cell (CTC)...

08:00
- Phase 1 study to examine safety and tolerability of U3-1402, a potential first-in-class HER3-targeting antibody drug conjugate (ADC), in patients with metastatic EGFR-mutated NSCLC - Patients with EGFR-mutated NSCLC who experience disease...

08:00
Array BioPharma Inc. and Pierre Fabre today announced results of the planned analysis of overall survival (OS) from the pivotal Phase 3 COLUMBUS trial in patients with BRAF-mutant melanoma. Treatment with the combination of encorafenib 450 mg daily...

1 2 3 4 5 6 7 8 9 10 11 12